186 related articles for article (PubMed ID: 22927522)
1. Progress against solid tumors in danger: the metastatic breast cancer example.
Cortés J; Calvo E; González-Martín A; Dawood S; Llombart-Cussac A; De Mattos-Arruda L; Gómez P; Silva O; Perez EA; Rugo HS; Lluch A; Hortobagyi GN
J Clin Oncol; 2012 Oct; 30(28):3444-7. PubMed ID: 22927522
[No Abstract] [Full Text] [Related]
2. Making genuine progress against metastatic breast cancer.
Lyman GH; Burstein HJ; Buzdar AU; D'Agostino R; Ellis PA
J Clin Oncol; 2012 Oct; 30(28):3448-51. PubMed ID: 22927527
[No Abstract] [Full Text] [Related]
3. Reputation and precedent in the bevacizumab decision.
Carpenter D; Kesselheim AS; Joffe S
N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
[No Abstract] [Full Text] [Related]
4. Pushing the envelope.
Nat Biotechnol; 2011 Aug; 29(8):669. PubMed ID: 21822220
[No Abstract] [Full Text] [Related]
5. Avastin saga reveals debate over clinical trial endpoints.
Sharma SP
J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
[No Abstract] [Full Text] [Related]
6. FDA cancels approval for bevacizumab in advanced breast cancer.
Tanne JH
BMJ; 2011 Nov; 343():d7684. PubMed ID: 22121166
[No Abstract] [Full Text] [Related]
7. Is the battle over bevacizumab coverage looming?
Larkin C
J Natl Compr Canc Netw; 2011 Mar; 9(3):261-3. PubMed ID: 21393437
[No Abstract] [Full Text] [Related]
8. Avastin for breast cancer, 2005-2011: requiescat in pacem?
Burstein HJ
J Natl Compr Canc Netw; 2011 Dec; 9(12):1321-3. PubMed ID: 22157551
[No Abstract] [Full Text] [Related]
9. FDA panel votes to pull Avastin in breast cancer, again.
Ratner M
Nat Biotechnol; 2011 Aug; 29(8):676. PubMed ID: 21822226
[No Abstract] [Full Text] [Related]
10. Bevacizumab recommendation highlights difficulties.
Printz C
Cancer; 2011 Nov; 117(22):5025. PubMed ID: 22052367
[No Abstract] [Full Text] [Related]
11. Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
Montero AJ; Escobar M; Lopes G; Glück S; Vogel C
Curr Oncol Rep; 2012 Feb; 14(1):1-11. PubMed ID: 22012632
[TBL] [Abstract][Full Text] [Related]
12. Changing end points in breast-cancer drug approval--the Avastin story.
D'Agostino RB
N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384
[No Abstract] [Full Text] [Related]
13. Avastin withdrawal symptoms.
Lynce F; Swain SM
Expert Opin Pharmacother; 2012 Feb; 13(3):293-8. PubMed ID: 22263961
[No Abstract] [Full Text] [Related]
14. Use of bevacizumab in the treatment of metastatic colorectal cancer.
Raouf S; Bridgewater J; Ellis R; Ferry D; Hill M; Wasan H
Br J Hosp Med (Lond); 2012 Jan; 73(1):25-30. PubMed ID: 22241406
[TBL] [Abstract][Full Text] [Related]
15. FDA. Once on 'fast track,' avastin now derailed.
Couzin-Frankel J; Ogale Y
Science; 2011 Jul; 333(6039):143-4. PubMed ID: 21737712
[No Abstract] [Full Text] [Related]
16. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D
Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120
[TBL] [Abstract][Full Text] [Related]
17. Reappraising antiangiogenic therapy for breast cancer.
Kerbel RS
Breast; 2011 Oct; 20 Suppl 3(0 3):S56-60. PubMed ID: 22015294
[TBL] [Abstract][Full Text] [Related]
18. Avastin hearing leads to more uncertainty over drug's future.
Goozner M
J Natl Cancer Inst; 2011 Aug; 103(15):1148-50. PubMed ID: 21768534
[No Abstract] [Full Text] [Related]
19. Avastin, ODAC, and the FDA: are we drafting the right players?
Burstein HJ
J Natl Compr Canc Netw; 2010 Aug; 8(8):833-4. PubMed ID: 20870630
[No Abstract] [Full Text] [Related]
20. Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?
Lohmann AE; Chia S
Curr Treat Options Oncol; 2012 Jun; 13(2):249-62. PubMed ID: 22350496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
